All these processes may result in a long-lasting progressive atrophy of gray and white matter [6]. TBI severity also ranges from mild to severe. Mild TBI is characterized by the absence of radiological abnormal
The main clinical features of blood stasis are fixed pain (worse at night), subcutaneous hematoma or purpura, and cyanosis of the face and lips [13]. The concept of headaches with blood stasis syndrome was first proposed by Qingren Wang from the Qing Dynasty in the Corrections on the Errors...
Consider 12-month outcomes of two cohorts employing the same stent: the RESILIENT study’s BMS arm reported a fracture rate of 3.1% for lesions averaging 7.1 cm (Figure 1; 25) compared with a fracture rate of 27.1% for lesions averaging 11.8 cm in the TIGRIS study BMS arm (Figure 1;...
See how much you know about the treatment of diabetic necrosis with this quiz and worksheet. The printable worksheet is perfect to track your...
The Federal Occupational Health (FOH) arm of the Department of Labor gives advice on injury prevention. One section concerns conditioning. The agency reminds you that you may have become deconditioned (i.e., out of shape) over the inactive winter months, so you should not expect to be able...
Damage to a major blood vessel within the head can cause a hematoma or heavy bleeding into or around the brain. Symptoms of a TBI may include headache, nausea, confusion or other cognitive problems, a change in personality, depression, irritability, and other emotional and behavioral problems. ...
or the generation of blood clots. In addition, splint placement requires perforation of the ventricular wall, which may lead to leakage problems such as hemorrhage or hematoma formation. Furthermore, because one end of the splint extends to the epicardial surface of the left ventricle, options for...
<div p-id="p-0001">A cardiac harness for treating congestive heart failure is disclosed. The harness applies elastic, compressive reinforcement on the left ventricle to reduce deleterious wall tension
Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeuti...
Dovlatova NL, Jakubowski JA, Sugidachi A, et al., The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function, J Thromb Haemost, 2008, pp. 1153-1159, vol. 6. Dovlatova N, Wijey...